Department of Internal Medicine "T", Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Ultrasound Med. 2022 Jul;41(7):1677-1687. doi: 10.1002/jum.15849. Epub 2021 Oct 26.
Safety precautions limit the clinical assessment of hospitalized Coronavirus disease 2019 (COVID-19) patients. The minimal exposure required to perform lung ultrasound (LUS) paired with its high accuracy, reproducibility, and availability make it an attractive solution for initial assessment of COVID-19 patients. We aim to evaluate whether the association between sonographic findings and clinical outcomes among COVID 19 patients is comparable between the validated 12-zone protocol and a shorter, 8-zone protocol, in which the posterior lung regions are omitted.
One hundred and one COVID-19 patients hospitalized in a dedicated COVID-19 ward in a tertiary referral hospital were examined upon admission and scored by 2 LUS protocols. The association between the scores and a composite outcome consisting of death, transfer to the intensive care unit (ICU) or initiation of invasive or noninvasive mechanical ventilation was estimated and compared.
LUS scores in both the 8- and the 12-zone protocols were associated with the composite outcome during hospitalization (hazard ratio [HR] 1.21 [1.03-1.42, P = .022] and HR 1.13 [1.01-1.27, P = .037], respectively). The observed difference in the discriminatory ROC-AUC values for the 8- and 12-zone scores was not significant (0.767 and 0.754 [P = .647], respectively).
A short 8-zone LUS protocol is as accurate as the previously validated, 12-zone protocol for prognostication of clinical deterioration in nonventilated COVID-19 patients.
安全预防措施限制了对住院的 2019 年冠状病毒病(COVID-19)患者的临床评估。进行肺部超声(LUS)所需的最小暴露量以及其高准确性、可重复性和可用性,使其成为 COVID-19 患者初始评估的理想选择。我们旨在评估在经过验证的 12 区方案和较短的 8 区方案中,COVID-19 患者的超声表现与临床结局之间的关联是否存在差异,在 8 区方案中省略了后肺区。
101 例 COVID-19 患者在一家三级转诊医院的专门 COVID-19 病房住院期间入院时接受检查,并通过 2 种 LUS 方案进行评分。评估评分与包括死亡、转入重症监护病房(ICU)或开始有创或无创机械通气的复合结局之间的关联,并进行比较。
在住院期间,8 区和 12 区方案的 LUS 评分均与复合结局相关(危险比[HR] 1.21[1.03-1.42,P=0.022]和 HR 1.13[1.01-1.27,P=0.037])。8 区和 12 区评分的观察到的判别 ROC-AUC 值差异无统计学意义(分别为 0.767 和 0.754[P=0.647])。
对于未接受通气的 COVID-19 患者,简短的 8 区 LUS 方案与先前验证的 12 区方案一样准确,可预测临床恶化的预后。